Skip to main content

It's our mission to help you get NULIBRY to your patients when they need it—because urgency is critical

ForgingBridges | NULIBRY Access and Support program gives you and your patients support during the benefits verification and prescription fulfillment process

Our support team collaborates with insurance companies to conduct the NULIBRY benefits verification process. We offer guidance when a NULIBRY claim is rejected, and can help with the prior authorization and appeals process.

forging bridges access support program logo

ForgingBridges | NULIBRY
Access and Support

For questions or additional info, give us a call. Our support team is ready to help.

Call 1-888-55BRIDGE
(1-888-552-7434)

Monday-Friday, 8 am-8 pm ET

The support you need starts here.

If you are a hospital or healthcare organization wanting to acquire NULIBRY, please call McKesson at ForgingBridges | NULIBRY at 1-888-55BRIDGE (1-888-552-7434).

If you are a caregiver and have any questions about NULIBRY or would like information about affordability options, please call ForgingBridges | NULIBRY at 1-888-55BRIDGE (1-888-552-7434) Monday-Friday, 8 am-8 pm ET. For inquiries after hours, follow the recorded instructions.

Your patient may be eligible for the ForgingBridges | NULIBRY Sample Program while under your care in the hospital. Contact ForgingBridges | NULIBRY to determine if your patient and institution qualify.

Request NULIBRY samples

The ForgingBridges | NULIBRY QuickStart Program may help patients who are prescribed NULIBRY and experiencing an insurance coverage determination delay of 5 or more days. Contact ForgingBridges | NULIBRY to learn more about this program and how your patient could be eligible to receive NULIBRY at no cost.

Patient Affordability Options >

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Potential for Photosensitivity

NULIBRY can make the patient oversensitive to sunlight. NULIBRY-treated patients or their caregivers are advised to avoid or minimize patient exposure to sunlight and artificial UV light and adopt precautionary measures when exposed to the sun, including wearing protective clothing and sunglasses, and use broad-spectrum sunscreen with high SPF in patients 6 months of age and older. If photosensitivity occurs, caregivers/patients are advised to seek medical attention immediately and consider a dermatological evaluation.

ADVERSE REACTIONS

The most common adverse reactions in NULIBRY-treated patients were infusion catheter–related complications (89%), pyrexia (fever) (78%), viral infection (56%), pneumonia (44%), otitis media (ear infection) (44%), vomiting (44%), and cough/sneezing (44%). Adverse reactions for rcPMP-treated patients were similar to the NULIBRY-treated patients.

PATIENT COUNSELING INFORMATION

Please read the FDA-approved NULIBRY Prescribing Information and Instructions for Use and follow the instructions on how to prepare and administer NULIBRY.

NULIBRY has a potential for photosensitivity; see Warnings and Precautions. Seek medical attention immediately if the patient develops a rash or if they notice symptoms of photosensitivity reactions (redness, burning sensation of the skin, blisters).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for NULIBRY.